Seeking Alpha

Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes...

Now that Amylin (AMLN) is being sold, Rodman & Renshaw's Michael King says fellow diabetes firms MannKind (MNKD +6.55%) and Vivus (VVUS +0.4%) could be acquisition targets as well. It's worth noting, though, that King's speculation accompanies a mea culpa for being wrong about Amylin, whose assets he described as "mediocre."
Comments (1)
  • buyitcheap
    , contributor
    Comments (1901) | Send Message
     
    A lot of early stage/3rd phase cos potentially in play with this move... the next round of M&A will clearly be pharma.
    2 Jul 2012, 02:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs